Syneos Health (SYNH) Enhances Clinical Trials With New Pact

Syneos Health, Inc. SYNH recently entered into a new strategic collaboration with Ride Health to provide non-emergency medical transportation (NEMT) to clinical trial participants. Furthermore, as part of the strategic relationship, Syneos Health made a minority investment in Ride Health.

The collaboration strengthens Syneos Health’s commitment to offer patient-centric, technology-enabled solutions that enhance the overall experience of clinical trials for sponsors, sites and patients.

The recent development is likely to strengthen Syneos Health Clinical Solutions.

About Ride Health

Ride Health’s HIPAA-compliant transportation solution is customized for clinical trial management, streamlining coordination across trial sponsors, contract research organizations (CROs), independent research sites, and trial participants.

The platform automatically matches each patient’s requirements to ensure consistent access to visits and prioritize patient centricity to the suitable transportation mode across standard curbside pickup, door-to-door assistance, and wheelchair accessible vehicles.

The web-based platform can be directly accessed on desktop or mobile devices, while a range of open APIs (application programming interface) directly allow integration with existing clinical trial management systems and patient-facing applications.

Zacks Investment ResearchImage Source: Zacks Investment Research

More on the News

Syneos Health and its trial sponsors have long acknowledged the benefit of transportation assistance to enhance patient access, recruitment and retention. The earlier approaches created considerable administrative burden for clinical trial coordinators and were limited to the scope of geographic and service level needs of enrolled patients.

In 2020, Syneos Health acquired U.K.-based Illingworth Research Group, which included PatientGo -- an in-house patient.

Ride Health’s technology-enabled approach and deep integration capabilities support PatientGo to simplify and add new efficiencies to its U.S.-based transportation operations, and speed up network development to develop a wide-ranging clinical trial platform.

Strategic Efforts

The collaboration between Ride Health and the Syneos Health patient engagement platform built on product integration will enable an inclusive transportation program for Syneos Health trials in the United States. This program has an objective of expanding access, minimizing burden and improving retention for patients while accelerating clinical trial recruitment for sponsors.

Together with Illingworth’s PatientGo services, the collaboration will help in bringing the clinical trial closer to patient, increasing diversity and accessibility, and further expanding the Dynamic Assembly network of preferred, best quality data and technology collaborators to boost the design and execution of clinical trials.

Ride Health’s solution connects directly with each stakeholder through its automated communication and support systems, enabling Syneos Health to minimize the coordination burden for site staff, improve patient experience, and advance retention across clinical trials.

Industry Prospects

Per a report by Grand View Research, the global clinical trials market size was estimated at $44.3 billion in 2020 and is expected to see a CAGR of 5.7%. The increasing incidence of chronic disease and the growing demand for clinical trials in developing countries are factors driving the market.

Recent Developments

In August 2021, Syneos Health announced a partnership with Aetion to offer regulatory-grade data and analytics-driven solutions to enhance drug development and improve patient outcomes. The partnership will allow biopharma companies to advance clinical development, market access and the uptake of new therapies.

In June 2021, Syneos Health expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group. This will help continue the momentum for Decentralized Solutions established by the acquisition of Illingworth Research Group to bring clinical trials closer to patients. The newly-established site advocacy group will provide deeper, more meaningful site-based insights to boost the adoption of decentralized clinical trials methodologies & technologies.

Price Performance

Shares of the company have gained 58.2% in a year’s time against the industry’s fall of 13.5%.

Zacks Rank and Key Picks

Currently, Syneos Health carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST, BellRing Brands, Inc. BRBR and Henry Schein, Inc. HSIC, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 27%.

BellRing Brands has an estimated long-term earnings growth rate of 29%.

Henry Schein has a projected long-term earnings growth rate of 14%.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 Crypto-Related Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Henry Schein, Inc. (HSIC): Free Stock Analysis Report
Syneos Health, Inc. (SYNH): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis Report
BellRing Brands, Inc. (BRBR): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.